Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone plus SPI-62 versus placebo in polymyalgia rheumatica
2024-517406-29-00Phase 2Completed
- Sponsor
- Sparrow Pharmaceuticals
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Prednisolone + SPI-62 with Prednisolone + placebo (2 arms). Primary endpoint: Inflammatory biomarkers. Started Nov 2024; status: completed.
02
Drugs
clofutriben
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2024-517406-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517406-29-00.